A comparison between adjuvant and delivering functions of calcium phosphate, aluminum hydroxide and chitosan nanoparticles, using a model protein of Brucella melitensis Omp31

被引:30
作者
Abkar, M. [1 ]
Alamian, S. [2 ]
Sattarahmady, N. [1 ,3 ]
机构
[1] Shiraz Univ Med Sci, Nanomed & Nanobiol Res Ctr, Shiraz, Iran
[2] Agr Res Educ & Org, Razi Vaccine & Serum Res Inst, Dept Brucella, Karaj, Iran
[3] Shiraz Univ Med Sci, Sch Med, Dept Med Phys, Shiraz, Iran
关键词
Ca-3(PO4)(2); Al(OH)(3); Vaccine delivery; Brucellosis; IMMUNE-RESPONSE; IN-VIVO; VACCINE DELIVERY; SIZE; IMMUNIZATION; GENERATION; PROTECTION; SALTS; VITRO; SHAPE;
D O I
10.1016/j.imlet.2019.01.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination is the most efficient and economic approach used to hinder infection and intense consequences caused by viruses, bacteria, or other pathogenic organisms. Since the intrinsic immunogenicity of recombinant antigens is usually low, safe and potent vaccine adjuvants are needed to ensure the success of those recombinant vaccines. Nanoparticles (NPs) have attracted much interest as adjuvants and delivery systems. Previous studies have shown that calcium phosphate (CP), aluminum hydroxide (AH) and chitosan (CS) NPs are promising delivery systems for immunization. In addition, it has been determined that Omp31 is a good candidate for inducing protection against Brucella (B) melitensis and B. ovis. Our aim in the present study was to compare the functions of CP, AH and CS NPs for stimulation of the immune response and protection against B. melitensis by using omp31 as a model protein. Based on the cytokine profile and subclasses of the antibody, vaccination with Omp31 load CP (CP/Omp31) and Omp31 load AH (AH/Omp31) NPs induced T helper type 1 (Th1)-T helper type 2 (Th2) immune response, whereas immunization by Omp31 load CS (CS/Omp31) NPs induced Th1 immune response. CP/Omp31 NPs elicited protection toward B. melitensis challenge equivalent to the vaccine strain B. melitensis Rev.l. Compared to CS/Omp31 NPs, CP/Omp31 NPs elicited a low increase in protection level against B. melitensis 16 M. In conclusion, the obtained results indicated that CP NPs were potent antigen delivery systems to immunize brucellosis.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 49 条
[1]  
Abkar M., 2018, IMMUNOL LETT
[2]   Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against Brucella melitensis infection [J].
Abkar, Morteza ;
Fasihi-Ramandi, Mahdi ;
Kooshki, Hamid ;
Lotfi, Abbas Sahebghadam .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 :8769-8778
[3]   Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections [J].
Abkar, Morteza ;
Amani, Jafar ;
Lotfi, Abbas Sahebghadam ;
Brujeni, Gholamreza Nikbakht ;
Alamian, Saeed ;
Kamali, Mehdi .
APMIS, 2015, 123 (08) :667-675
[4]   Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].
Agnihotri, SA ;
Mallikarjuna, NN ;
Aminabhavi, TM .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28
[5]   Aluminum hydroxide nanoparticles show strong activity to stimulate Th-1 immune response against tuberculosis [J].
Amini, Yousef ;
Moradi, Bagher ;
Fasihi-Ramandi, Mahdi .
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2017, 45 (07) :1331-1335
[6]   TB trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice [J].
Amini, Yousef ;
Moradi, Bagher ;
Tafaghodi, Mohsen ;
Meshkat, Zahra ;
Ghazvini, Kiarash ;
Fasihi-Ramandi, Mahdi .
BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, 2016, 21 (05) :653-658
[7]   Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51 [J].
Ashford, DA ;
di Pietra, J ;
Lingappa, J ;
Woods, C ;
Noll, H ;
Neville, B ;
Weyant, R ;
Bragg, SL ;
Spiegel, RA ;
Tappero, J ;
Perkins, BA .
VACCINE, 2004, 22 (25-26) :3435-3439
[8]   Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns [J].
Bachmann, Martin F. ;
Jennings, Gary T. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (11) :787-796
[9]   Aluminum salts in vaccines - US perspective [J].
Baylor, NW ;
Egan, W ;
Richman, P .
VACCINE, 2002, 20 :S18-S23
[10]   Designing and building the next generation of improved vaccine adjuvants [J].
Brito, Luis A. ;
O'Hagan, Derek T. .
JOURNAL OF CONTROLLED RELEASE, 2014, 190 :563-579